JP2006502963A5 - - Google Patents

Download PDF

Info

Publication number
JP2006502963A5
JP2006502963A5 JP2003564026A JP2003564026A JP2006502963A5 JP 2006502963 A5 JP2006502963 A5 JP 2006502963A5 JP 2003564026 A JP2003564026 A JP 2003564026A JP 2003564026 A JP2003564026 A JP 2003564026A JP 2006502963 A5 JP2006502963 A5 JP 2006502963A5
Authority
JP
Japan
Prior art keywords
optionally substituted
furan
oxo
hydroxy
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003564026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502963A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/002766 external-priority patent/WO2003064403A1/en
Publication of JP2006502963A publication Critical patent/JP2006502963A/ja
Publication of JP2006502963A5 publication Critical patent/JP2006502963A5/ja
Pending legal-status Critical Current

Links

JP2003564026A 2002-01-31 2003-01-30 フラノン誘導体 Pending JP2006502963A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35393902P 2002-01-31 2002-01-31
PCT/US2003/002766 WO2003064403A1 (en) 2002-01-31 2003-01-30 Furanone derivatives

Publications (2)

Publication Number Publication Date
JP2006502963A JP2006502963A (ja) 2006-01-26
JP2006502963A5 true JP2006502963A5 (cg-RX-API-DMAC7.html) 2006-04-20

Family

ID=27663268

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003564026A Pending JP2006502963A (ja) 2002-01-31 2003-01-30 フラノン誘導体

Country Status (8)

Country Link
US (1) US6667330B2 (cg-RX-API-DMAC7.html)
EP (1) EP1478634A4 (cg-RX-API-DMAC7.html)
JP (1) JP2006502963A (cg-RX-API-DMAC7.html)
AU (1) AU2003207750A2 (cg-RX-API-DMAC7.html)
CA (1) CA2474871A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA04007292A (cg-RX-API-DMAC7.html)
NZ (1) NZ534305A (cg-RX-API-DMAC7.html)
WO (1) WO2003064403A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985771B2 (en) * 2002-01-31 2011-07-26 Monsanto Technology Llc Furanone derivatives
US20040156874A1 (en) * 2003-02-11 2004-08-12 Bradley Pharmaceuticals, Inc. Urea- a topical anti-inflammatory
TW200600091A (en) * 2004-05-21 2006-01-01 Telik Inc Sulfonylethyl phosphorodiamidates
EA035619B1 (ru) 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
PL2220030T3 (pl) 2007-11-06 2016-07-29 Bioelectron Tech Corp Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych
EP2237664A4 (en) 2008-01-08 2013-05-22 Edison Pharmaceuticals Inc (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
EP2303824B1 (en) 2008-06-25 2015-03-25 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
CA2740773A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
WO2010051277A1 (en) 2008-10-28 2010-05-06 Edison Pharmaceuticals, Inc. Process for the production of alpha-tocotrienol and derivatives
CA2777479C (en) 2009-04-28 2017-10-17 Ptc Therapeutics, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
CA2842486C (en) 2011-07-19 2022-09-06 Edison Pharmaceuticals, Inc. Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
EP3345596B1 (en) 2012-09-21 2021-01-20 Rhode Island Hospital Inhibitors of beta-hydrolase for treatment of cancer
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
HUE058877T2 (hu) 2014-12-16 2022-09-28 Ptc Therapeutics Inc (R)-2-hidroxi-2-metil-4-(2,4,5-trimetil-3,6-dioxociklohexa-1,4-dienil)butánamid polimorf és amorf alakjai
JP7117241B2 (ja) 2015-12-16 2022-08-12 ピーティーシー セラピューティクス, インコーポレイテッド 混合されたトコール組成物からアルファ-トコトリエノールを富化するための改良された方法
EP3389646A1 (en) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩
HUE066196T2 (hu) 2018-10-17 2024-07-28 Ptc Therapeutics Inc 2,3,5-trimetil-6-nonilciklohexa-2,5-dién-1,4-dion alfa-szinukleinopátiák, tauopátiák és egyéb rendellenességek szuppresszálására és kezelésére
EP4366700A1 (en) 2021-07-08 2024-05-15 PTC Therapeutics, Inc. Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4875564A (cg-RX-API-DMAC7.html) 1972-01-08 1973-10-11
JPS4988862A (cg-RX-API-DMAC7.html) 1972-12-29 1974-08-24
JPH06100445A (ja) 1992-07-06 1994-04-12 Banyu Pharmaceut Co Ltd 抗腫瘍剤
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5464865A (en) * 1993-12-22 1995-11-07 Ortho Pharmaceutical Corporation 4-aryl- and 4-arylthio-5-hydroxy-2(5H)-furanones as inhibitors of phospholipase A2
JPH07206841A (ja) 1994-01-20 1995-08-08 Sankyo Co Ltd ブチロラクトンの製造法
US6020343A (en) 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US5756518A (en) * 1996-04-02 1998-05-26 Kowa Co., Ltd. Phenylene derivatives
WO1997037985A1 (en) * 1996-04-10 1997-10-16 Warner-Lambert Company Nonpeptide endothelin antagonists with increased water solubility
US6005000A (en) * 1996-08-22 1999-12-21 Oxis International, Inc. 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
WO2000061571A1 (en) * 1999-04-14 2000-10-19 Pacific Corporation 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors
US6576662B2 (en) * 2000-05-05 2003-06-10 Dr. Reddy's Laboratories Limited Compounds having anticancer activity : process for their preparation and pharmaceutical compositions containing them

Similar Documents

Publication Publication Date Title
US10442782B2 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN109863140B (zh) 3-氧代-2,6-二苯基-2,3-二氢哒嗪-4-甲酰胺
US9649310B2 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN113710656B (zh) 作为法尼醇x受体调节剂的经取代的双环化合物
AU2011242569B2 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
CA2729557A1 (en) Chemical compounds 251
KR20120131161A (ko) 특정 키뉴레닌-3-모노옥시게나제 억제제, 그의 제약 조성물 및 사용 방법
JP2002527419A (ja) Gsk−3阻害物質としてのピロール−2,5−ジオン類
US20110275610A1 (en) Substituted pyrazole compounds
CA2731097A1 (en) Organic compounds
JP2014506585A (ja) キナーゼ阻害剤としてのチアゾリルフェニル−ベンゼンスルホンアミド誘導体
WO2004047760A2 (en) Novel chemical compounds
JP2008523041A5 (cg-RX-API-DMAC7.html)
RS54718B1 (sr) Derivati 1,2,4-tiazolidin-3-ona i njihova upotreba u lečenju kancera
US20200347053A1 (en) Substituted pyrrolopyridines as jak inhibitors
JP2002505329A (ja) ロータマーゼ酵素の阻害剤としての複素環式化合物
AU2017275209A1 (en) Sulfonamide compound or salt thereof
ES2525298T3 (es) Compuestos heterocíclicos como agonistas del S1P1 para el tratamiento de enfermedades autoinmunes y vasculares
WO2006011631A2 (en) Thiazole derivatives having vap-1 inhibitory activity
CA2672307A1 (en) Bipiperidinyl compounds, compositions containing such compounds and methods of treatment
ES2533095T3 (es) Agonistas de receptores de esfingosina-1-fosfato
US20210380533A1 (en) 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
CN101104617A (zh) 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
BRPI0817824B1 (pt) derivados de (r)-4-(heteroaril) feniletila, composições farmacêuticas e processo para preparação dos mesmos
WO2011133734A1 (en) 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists